News | Radiation Oncology | July 13, 2015

Mirada Medical to Highlight Quality Assurance of Deformable Image Registration at AAPM

Company's RegistrationQX platform provides automated, quantitative assessment of DIR to eliminate inter-user variability

Mirada Medical, deformable image registration, DIR, QA, RegistrationQX, AAPM

July 13, 2015 - Mirada Medical and collaborators from the University Medical Center, Groningen, The Netherlands, will present new research on quality assurance of deformable image registration (DIR) at the annual meeting of the American Association of Medical Physicists (AAPM). Accurate definition of targets and critical structures is essential for the planning and delivery of radiation therapy and radiosurgery. DIR is increasingly utilized during treatment planning to aid in this process.

A critical step in deploying DIR in the clinic is quality assurance of the result. To date, this has been typically performed qualitatively using tools such as fusion overlays and inspection of the deformation field, requiring a user experienced with DIR, patient anatomy and the clinical context. Such an approach is subjective and can lead to significant inter-user variability. Existing quantitative tools such as measuring target registration error and dice overlap of structures are practical for commissioning and research but are often too labor-intensive for clinical use.

Mirada Medical and collaborators will be introducing RegistrationQX, a novel technique to overcome these limitations. RegistrationQX uses a set of quantitative measurements of the deformation quality, numerical robustness and matching to assist the user in assessing the quality of a DIR result. With the release of RegistrationQX, clinical staff will be able to augment their visual DIR quality assurance with an automatically generated quantitative report. The original research compares the quantitative scores produced by RegistrationQX with grading scores produced by experts with significant experience in using DIR clinically on 27 head and neck patients. Good correlation (0.86) was observed between the automatic and manual scores indicating that the quantitative scores reflected the opinions of the experts.

RegistrationQX and this study form part of Mirada's Registration Assurance program, a comprehensive program for ensuring DIR quality and continuous improvement through rigorous scientific validation of technology, education, comprehensive QC tools and a commitment to ongoing development and support. The registration workflows used in the study are all available in the new releases of Mirada RTx and Mirada Workflow Box.

For more information: www.mirada-medical.com

Related Content

Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
Varian Acquires Mobius Medical Systems
News | Quality Assurance (QA) | February 06, 2018
February 6, 2018 – Varian announced it has acquired privately-held Mobius Medical Systems, a...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
RayStation Selected for India’s First Proton Center
News | Proton Therapy | February 01, 2018
February 1, 2018 – Apollo Hospitals, Asia´s foremost integrated healthcare provider, has selected RayStation for a ne
RayStation Selected for London's Charing Cross Hospital and Hammersmith Hospital
News | Treatment Planning | January 30, 2018
Imperial College Healthcare NHS Trust in London, U.K., has chosen RayStation as the sole treatment planning system for...
Small-Cell Lung Cancer Patients Face Barriers to Standard-of-Care Treatment
News | Lung Cancer | January 29, 2018
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the...
Advaxis Immunotherapy Offers Potential Combo Treatment for Anal Cancer
News | Radiation Therapy | January 26, 2018
January 26, 2018 — Advaxis Inc.
Overlay Init